Gritstone bio

Gritstone bio is a clinical-stage American biotechnology company which develops cancer and infectious disease immunotherapies and vaccines. It was founded in August 2015 as Gritstone Oncology, Inc., and is based in Emeryville, California.[1]

In September 2021 it raised $55.0 million from the sale of 5,000,000 shares.[2]

It started a Phase 1 trial of its self-amplifying mRNA second generation SARS-CoV-2 vaccine, GRT-R910, in the NIHR Manchester Clinical Research Facility at Manchester Royal Infirmary, in September 2021.[3] This is to explore the ability of GRT-R910 to boost and expand the immunogenicity of AstraZeneca's first-generation COVID-19 vaccine AZD1222 (Vaxzevria) in healthy adults of more than 60 years. It uses lipid nanoparticles to deliver a broad set of antigens against SARS-CoV-2 that includes both stabilized spike protein and highly conserved viral protein regions containing T cell epitopes.[4] Prof. Andrew Ustianowski is the study’s chief investigator.[5]

On 10 November 2021, Gritstone announced positive preclinical data of its second-generation self-amplifying mRNA (SAM) vaccine against SARS-CoV-2 in non-human primate models.[6]

It is involved in a Phase 1/2 study, in collaboration with Bristol-Myers Squibb, in 26 patients with metastatic solid tumors.[7]

References

  1. ↑ "About us". Gritstone bio. Retrieved 22 September 2021.
  2. ↑ "Gritstone Announces Private Placement Financing of $55.0 Million". Globe Newswire. 16 September 2021. Retrieved 22 September 2021.
  3. ↑ "Early trial of multivariant COVID-19 vaccine booster begins in Manchester". ManchesterUniversity. 20 September 2021. Retrieved 22 September 2021.
  4. ↑ "Gritstone Bio Doses First Volunteer In Phase 1 Trial Of GRT-R910 As COVID-19 Vaccine Booster". Nasdaq. 20 September 2021. Retrieved 22 September 2021.
  5. ↑ "Trial of first COVID-19 variant-proof jab begins in UK". Arab News. 21 September 2021. Retrieved 22 September 2021.
  6. ↑ Inc, Gritstone bio (2021-11-10). "Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2". GlobeNewswire News Room (Press release). Retrieved 2021-12-06. {{cite press release}}: |last= has generic name (help)
  7. ↑ "Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE "Off-the-Shelf" Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial". Global Newswire. 17 September 2021. Retrieved 22 September 2021.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.